Last reviewed · How we verify

Estradiol valerate / dienogest — Competitive Intelligence Brief

Estradiol valerate / dienogest (Estradiol valerate / dienogest) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive (combined estrogen-progestin). Area: Contraception / Gynecology.

marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor and progesterone receptor Contraception / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Estradiol valerate / dienogest (Estradiol valerate / dienogest) — Helsinki University Central Hospital. Estradiol valerate and dienogest work together as a hormonal contraceptive by suppressing ovulation through progestin and estrogen activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Estradiol valerate / dienogest TARGET Estradiol valerate / dienogest Helsinki University Central Hospital marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor and progesterone receptor
Ethinylestradiol / Norethisterone Ethinylestradiol / Norethisterone University of Edinburgh marketed Combined oral contraceptive Estrogen receptor and progesterone receptor
ETHINYL ESTRADIOL AND LEVOGESTREL ETHINYL ESTRADIOL AND LEVOGESTREL FHI 360 marketed Combined oral contraceptive Estrogen receptor and progesterone receptor
OCR OCR Hoffmann-La Roche marketed Combined oral contraceptive Estrogen receptor and progesterone receptor
ethinyl estradiol/etonogestrel vaginal ring ethinyl estradiol/etonogestrel vaginal ring University of Pittsburgh marketed Combined hormonal contraceptive Estrogen receptor and progesterone receptor
ethinyl estradiol/norelgestromin transdermal contraceptive ethinyl estradiol/norelgestromin transdermal contraceptive University of Pittsburgh marketed Hormonal contraceptive Estrogen receptor and progesterone receptor
Ethinyl Estradiol / Norgestimate Oral Tablet Ethinyl Estradiol / Norgestimate Oral Tablet University of Colorado, Denver marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor and progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive (combined estrogen-progestin) class)

  1. Bayer · 3 drugs in this class
  2. Organon and Co · 2 drugs in this class
  3. Teva Pharmaceuticals USA · 2 drugs in this class
  4. University of Colorado, Denver · 1 drug in this class
  5. Oregon Health and Science University · 1 drug in this class
  6. Helsinki University Central Hospital · 1 drug in this class
  7. Ironwood Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estradiol valerate / dienogest — Competitive Intelligence Brief. https://druglandscape.com/ci/estradiol-valerate-dienogest. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: